The effects of neurotransmitters and other cellular modulators and factors on hypothalamic and anterior pituitary delta 4-steroid (progesterone) 5 alpha-reductase activity.
A number of diverse biological compounds involved in the regulation of the hypothalamo-hypophyseal-ovarian axis have been examined for effects on the conversion of 3H-progesterone to 3H-5 alpha-dihydro-progesterone and 3H-3 alpha-hydroxy-5 alpha-pregnan-20-one by female rat hypothalamus and/or anterior pituitary. Broken cell preparations were incubated with 3H-progesterone and NADPH, and product 5 alpha-reduced progestins were quantitated by reverse isotopic dilution analysis. Progesterone 5 alpha-reductase activity was reduced up to 50% in the presence of 10(-2) to 10(-3) M serotonin in both preparations. At 10(-3) M, various indoles including n-acetylserotonin, melatonin, 5-methoxytryptamine, 5-methoxytryptophol, and 5-hydroxyindole acetic acid decreased by 10 to 30% 5 alpha-reduced product formation. At 10(-2) M, carbamylcholine and norepinephrine were without effect, while 10(-2) M dopamine reduced by 20% the 5 alpha-reduction of progesterone only in pituitary homogenates. The LHRH protease inhibitor bacitracin (2 X 10(-3) M) decreased by 10 to 40% progesterone 5 alpha-reductase activity in both tissues. By itself, LHRH did not affect the 5 alpha-reduction of progesterone nor did it potentiate the bacitracin effect. In the presence of 1 mM ATP, 100 micronM cAMP and 100 micronM cGMP increased 5 alpha-reduced product formation in the hypothalamus by 19 and 14%. The gonadotropins LH and FSH and the prostaglandins E1, E2, F1 alpha, and F2 alpha were without effect. Thus, these results and others indicate that a number of cellular components and other factors can affect the in vitro 5 alpha-reduction of progesterone in broken cell preparations.
D004092:20-alpha-Dihydroprogesterone / Q000032:analysis; D015096:3-Hydroxysteroid Dehydrogenases / Q000378:metabolism*; D000818:Animals; D001205:Ascorbic Acid; D001414:Bacitracin / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology; D004492:Edetic Acid; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000494:pharmacology; D007031:Hypothalamus / Q000201:enzymology*; D007033:Hypothalamus, Middle / Q000201:enzymology*; D018377:Neurotransmitter Agents / Q000494:pharmacology*; D010293:Pargyline / Q000494:pharmacology; D010903:Pituitary Gland, Anterior / Q000201:enzymology*; D011375:Progesterone Reductase / Q000378:metabolism*; D051381:Rats; D012701:Serotonin / Q000494:pharmacology; D012702:Serotonin Antagonists / Q000494:pharmacology
D018377:Neurotransmitter Agents; D012702:Serotonin Antagonists; D001414:Bacitracin; D004092:20-alpha-Dihydroprogesterone; D012701:Serotonin; D007987:Gonadotropin-Releasing Hormone; D004492:Edetic Acid; D010293:Pargyline; D015096:3-Hydroxysteroid Dehydrogenases; D011375:Progesterone Reductase; D001205:Ascorbic Acid; D004298:Dopamine